<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00801879</url>
  </required_header>
  <id_info>
    <org_study_id>AAAB0129</org_study_id>
    <secondary_id>K08AI072043</secondary_id>
    <nct_id>NCT00801879</nct_id>
  </id_info>
  <brief_title>Mupirocin Ointment to Eliminate Nasal Carriage of Staphylococcus Aureus in HIV Infection</brief_title>
  <official_title>Intranasal Mupirocin to Eliminate Carriage of Staphylococcus Aureus in HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Staphylococcus aureus is a bacteria that causes serious, often life threatening infections
      including pneumonia, wound, and bloodstream infections. Persons with AIDS are at high risk
      for S. aureus infections. They are also at high risk for nasal carriage of S. aureus. In
      fact, nasal carriage is a known risk factor for subsequent S. aureus infection. Topical
      mupirocin, an antibiotic when applied to the anterior nares, is a safe, effective way to
      eliminate S. aureus colonization. Some studies have shown that mupirocin can also decrease
      the risk of S. aureus infection, but many of those studies utilized historical controls and
      none were rigorously tested among AIDS patients over an extended period of time.

      The main purpose of this randomized, double-blinded, placebo controlled study is to determine
      if mupirocin can eliminate S. aureus nasal colonization in residents at PSI (inpatient, drug
      rehabilitation facility for AIDS patients in the Bronx.) PSI residents currently have a high
      incidence of S. aureus nasal colonization and infection. Nasal cultures followed by twice
      daily application of mupirocin vs. placebo for five days will be performed on a monthly basis
      for 8 months. the study will examine whether mupirocin decreases the incidence of S. aureus
      infections and prevents S. aureus nasal colonization. The study is important because it may
      show that mupirocin is an effective way to eliminate nasal colonization and prevent S. aureus
      infections in AIDS patients, among those at highest risk for serious S. aureus infection.

      Hypothesis: Monthly application of mupirocin will reduce nasal colonization with S.aureus
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a randomized double-blinded placebo controlled trial. Subjects were treated with
      intranasal mupirocin or placebo on a monthly basis and tested for nasal colonization a month
      after each treatment. This was performed up to 8 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nasal colonization with Staphylococcus aureus</measure>
    <time_frame>monthly assessment of colonization (~1 month after each treatment)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infection with Staphylococcus aureus</measure>
    <time_frame>monthly</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Staphylococcus Aureus</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Mupirocin ointment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.25g mupirocin calcium ointment, 2% in each nostril twice daily for 5 days (repeated monthly for up to 8 months)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo ointment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.25g in each nostril twice daily for 5 days (repeated monthly for up to 8 months)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mupirocin calcium ointment, 2%</intervention_name>
    <description>0.25 g in each nostril twice daily for 5 days (given monthly for up to 8 months)</description>
    <arm_group_label>Mupirocin ointment</arm_group_label>
    <other_name>Bactroban Nasal 2%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo ointment</intervention_name>
    <description>Placebo ointment 0.25g in each nostril twice daily for 5 days (repeated monthly for up to 8 months)</description>
    <arm_group_label>Placebo ointment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Resident at Project Samaritan Inc. (PSI)

        Exclusion Criteria:

          -  Past hypersensitivity to mupirocin or glycerol

          -  Pregnancy

          -  Lactation

          -  Expected discharge from PSI in the following month

          -  Treatment with intranasal mupirocin within the preceding two months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachel J Gordon, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franklin D Lowy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Project Samaritan Inc.</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Gordon RJ, Chez N, Jia H, Zeller B, Sobieszczyk M, Brennan C, Hisert KB, Lee MH, Vavagiakis P, Lowy FD. The NOSE study (nasal ointment for Staphylococcus aureus eradication): a randomized controlled trial of monthly mupirocin in HIV-infected individuals. J Acquir Immune Defic Syndr. 2010 Dec;55(4):466-72. doi: 10.1097/QAI.0b013e3181ec2a68.</citation>
    <PMID>20686410</PMID>
  </results_reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2008</study_first_submitted>
  <study_first_submitted_qc>December 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2008</study_first_posted>
  <last_update_submitted>October 28, 2014</last_update_submitted>
  <last_update_submitted_qc>October 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Franklin D. Lowy</investigator_full_name>
    <investigator_title>Professor of Medicine and Pathology at the New York-Presbyterian Hospital at the Columbia University Medical Center</investigator_title>
  </responsible_party>
  <keyword>mupirocin</keyword>
  <keyword>Staphylococcus aureus</keyword>
  <keyword>colonization</keyword>
  <keyword>infection</keyword>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mupirocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

